Skip to main content

Meticuly

ApplicationBangkok, ThailandFounded 2017· One of 381 Application companies tracked by AMPulse

A deep-tech medical company specializing in AI-driven, 3D-printed patient-specific titanium bone implants and surgical solutions.

CEO / Founder
Andy Choi
Team Size
51-200
Stage
Growth Stage
Total Funding
$8.65M
Latest Round
Series B
Key Investors
BE Healthcare Ventures, Expara, Digital Ventures, Chulalongkorn University Innovation Hub

Technology & Products

Key Products

["Craniomaxillofacial (CMF) Implants (Cranial, Facial, and Mandibular reconstruction)","Orthopedic Solutions (Patient-specific Hip and Spine implants)","AI-Powered Design Software (Proprietary digital platform for surgeon-led implant design)","Anatomical Models and Surgical Guides (3D-printed tools for pre-surgical planning)"]

Technological Advantage

Proprietary AI design modules significantly reduce the time required for custom implant engineering from weeks to days, supported by two FDA 510(k) clearances (2022 and 2024) for global commercial scalability.

Differentiation

Value Proposition

Delivers personalized, high-precision bone replacements with a rapid turnaround time, improving surgical accuracy and patient recovery while reducing operating room costs.

How They Differentiate

Meticuly differentiates through its proprietary AI-driven design platform that automates the creation of patient-specific implants, reducing the design-to-delivery cycle from weeks to just a few days. This digital-first workflow offers higher precision and significantly lower costs compared to traditional manual design processes used by global incumbents.

Market & Competition

Target Customers

Orthopedic and neurosurgeons, specialized medical institutions, and private/public hospital networks.

Industry Verticals

["Healthcare","Medical Devices","Additive Manufacturing (3D Printing)","Artificial Intelligence"]

Competitors

Materialise, Anatomics, Stryker (Patient Specific Solutions)

Growth & Milestones

Growth Metrics

Partnered with over 150 hospitals worldwide; holds 70+ global intellectual properties; secured two separate FDA 510(k) clearances for global market scalability.

Major Milestones

["Secured first FDA 510(k) clearance for Craniomaxillofacial (CMF) implants in 2022","Successfully closed Series B funding round in January 2024","Secured second FDA 510(k) clearance for Orthopedic and Spine solutions in 2024","Recognized as a WIPO IP Champion and selected for global showcase at Expo 2025 Osaka"]

Notable Customers

Chulalongkorn Hospital, Siriraj Hospital, Bumrungrad International Hospital, Faculty of Medicine Ramathibodi Hospital

https://www.meticuly.com

Why this company matters

Meticuly occupies a distinctive position in the personalized medical implant market by bridging the gap between high-end custom solutions and affordable mass-market orthopedic devices. Based in Bangkok, the deep-tech company competes with global incumbents such as Materialise, Anatomics, and Stryker by offering a digital-first workflow that reduces design-to-delivery cycles from weeks to a few days.

The core technology integrates proprietary AI-assisted anatomical analysis with metal laser powder bed fusion (PBF-LB) to produce patient-specific titanium bone implants. Meticuly's product line includes craniomaxillofacial implants for cranial, facial, and mandibular reconstruction, as well as orthopedic solutions for hip and spine procedures. The company also provides 3D-printed anatomical models and surgical guides for pre-surgical planning.

Target customers include orthopedic and neurosurgeons at specialized medical institutions and hospital networks. Named clinical partners include Chulalongkorn Hospital, Siriraj Hospital, Bumrungrad International Hospital, and the Faculty of Medicine Ramathibodi Hospital. Meticuly has partnered with over 150 hospitals worldwide and secured two FDA 510(k) clearances, one for CMF implants in 2022 and another for orthopedic and spine solutions in 2024.

The company's strategic moat rests on its proprietary AI design modules, which automate implant engineering and significantly lower costs compared to manual design processes used by established competitors. Meticuly has raised $8.65 million from investors including BE Healthcare Ventures, Expara, and Digital Ventures. A key open question is whether the company can scale its personalized workflow beyond its current hospital network and maintain regulatory momentum across additional geographies.